BC Week In Review | Apr 23, 2012
Clinical News

KeyPath MRSA/MSSA Blood Culture Test-BT regulatory update

FDA granted 510(k) clearance to include the use of 4 BD Bactec blood culture bottles for Microphage's KeyPath MRSA/MSSA Blood Culture Test-BT to identify Staphylococcus aureus and determine methicillin resistance (MRSA) or susceptibility (MSSA) in...
BC Week In Review | Oct 17, 2011
Company News

Cardinal Health, Microphage sales and marketing update

MicroPhage granted Cardinal Health exclusive U.S. and Canadian commercialization rights to KeyPath MRSA/MSSA Blood Culture Test and other undisclosed products in development to detect Staphylococcus aureus. Cardinal will fund development and commercialization of the products....
BC Week In Review | May 16, 2011
Clinical News

KeyPath MRSA/MSSA Blood Culture Test regulatory update

FDA granted 510(k) clearance to Microphage's KeyPath MRSA/MSSA Blood Culture Test to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. The company expects to launch the product in...
BC Week In Review | Feb 14, 2011
Company News

Microphage management update

Microphage Inc. , Longmont, Colo.   Business: Diagnostic   Hired: Don Mooney as CEO, formerly president and CEO of ProteoGenix Inc. ; he replaces interim CEO Drew Smith, who will remain CSO  ...
BC Week In Review | May 31, 2010
Company News

Microphage sales and marketing update

MicroPhage launched its Microphage MRSA/MSSA blood culture test outside the U.S. to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. In March, MicroPhage submitted a 510(k) application to...
BC Week In Review | Apr 5, 2010
Company News

AspenBio management update

AspenBio Pharma Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Veterinary, Diagnostic, Supply/Service   Hired: Steve Lundy as CEO and a director, formerly CEO of MicroPhage Inc.; he replaces interim CEO Daryl Faulkner, who will remain...
BC Week In Review | Mar 29, 2010
Company News

Microphage management update

MicroPhage Inc. , Longmont, Colo.   Business: Diagnostic   Promoted: Alene Campbell to CEO from COO; she replaces Steve Lundy, who resigned  ...
BC Week In Review | Mar 15, 2010
Clinical News

MRSA/MSSA blood culture test regulatory update

MicroPhage submitted a 510(k) application to FDA for its Microphage MRSA/MSSA blood culture test to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. The test, which uses MicroPhage's...
BC Week In Review | Dec 14, 2009
Clinical News

MRSA/MSSA blood culture test regulatory update

Microphage received CE Mark approval in the EU for its MRSA/MSSA Blood Culture Test to identify staphylococcus aureus bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia. Microphage began a...
BC Week In Review | Aug 31, 2009
Clinical News

MRSA/MSSA blood culture test: Pivotal trial started

Microphage began a U.S. pivotal trial to evaluate its MRSA/MSSA blood culture test in about 700 patients. Microphage Inc. , Longmont, Colo.   Product: MRSA/MSSA blood culture test   Business: Diagnostic   Molecular target: NA  ...
Items per page:
1 - 10 of 11
BC Week In Review | Apr 23, 2012
Clinical News

KeyPath MRSA/MSSA Blood Culture Test-BT regulatory update

FDA granted 510(k) clearance to include the use of 4 BD Bactec blood culture bottles for Microphage's KeyPath MRSA/MSSA Blood Culture Test-BT to identify Staphylococcus aureus and determine methicillin resistance (MRSA) or susceptibility (MSSA) in...
BC Week In Review | Oct 17, 2011
Company News

Cardinal Health, Microphage sales and marketing update

MicroPhage granted Cardinal Health exclusive U.S. and Canadian commercialization rights to KeyPath MRSA/MSSA Blood Culture Test and other undisclosed products in development to detect Staphylococcus aureus. Cardinal will fund development and commercialization of the products....
BC Week In Review | May 16, 2011
Clinical News

KeyPath MRSA/MSSA Blood Culture Test regulatory update

FDA granted 510(k) clearance to Microphage's KeyPath MRSA/MSSA Blood Culture Test to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. The company expects to launch the product in...
BC Week In Review | Feb 14, 2011
Company News

Microphage management update

Microphage Inc. , Longmont, Colo.   Business: Diagnostic   Hired: Don Mooney as CEO, formerly president and CEO of ProteoGenix Inc. ; he replaces interim CEO Drew Smith, who will remain CSO  ...
BC Week In Review | May 31, 2010
Company News

Microphage sales and marketing update

MicroPhage launched its Microphage MRSA/MSSA blood culture test outside the U.S. to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. In March, MicroPhage submitted a 510(k) application to...
BC Week In Review | Apr 5, 2010
Company News

AspenBio management update

AspenBio Pharma Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Veterinary, Diagnostic, Supply/Service   Hired: Steve Lundy as CEO and a director, formerly CEO of MicroPhage Inc.; he replaces interim CEO Daryl Faulkner, who will remain...
BC Week In Review | Mar 29, 2010
Company News

Microphage management update

MicroPhage Inc. , Longmont, Colo.   Business: Diagnostic   Promoted: Alene Campbell to CEO from COO; she replaces Steve Lundy, who resigned  ...
BC Week In Review | Mar 15, 2010
Clinical News

MRSA/MSSA blood culture test regulatory update

MicroPhage submitted a 510(k) application to FDA for its Microphage MRSA/MSSA blood culture test to identify Staphylococcus aureus bacteria and determine methicillin resistance or susceptibility in suspected cases of bacteremia. The test, which uses MicroPhage's...
BC Week In Review | Dec 14, 2009
Clinical News

MRSA/MSSA blood culture test regulatory update

Microphage received CE Mark approval in the EU for its MRSA/MSSA Blood Culture Test to identify staphylococcus aureus bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia. Microphage began a...
BC Week In Review | Aug 31, 2009
Clinical News

MRSA/MSSA blood culture test: Pivotal trial started

Microphage began a U.S. pivotal trial to evaluate its MRSA/MSSA blood culture test in about 700 patients. Microphage Inc. , Longmont, Colo.   Product: MRSA/MSSA blood culture test   Business: Diagnostic   Molecular target: NA  ...
Items per page:
1 - 10 of 11